Wyeth and Progenics Obtain Positive Opinion From European Agency for Relistor
Posted on: Friday, 25 April 2008, 03:00 CDT
Wyeth Pharmaceuticals, a division of Wyeth and Progenics Pharmaceuticals have received a positive opinion for Relistor subcutaneous injection from the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency.
The companies are seeking approval for Relistor in Europe for the treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
The Committee for Medicinal Products for Human Use (CHMP) is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion will now be forwarded to the European Commission for a final decision, which is anticipated by mid-2008.
Source: Datamonitor
Related Articles
- Leaders in Healthcare to Examine Impact of Comparative Effectiveness Research on Personalized Medicine
- NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
- Significance of Medicare and Medicaid Programs for the Practice of Medicine
- W.Va. Could Lead Nation in Health-Care Solution
- HealthPartners Chief Health Officer Appointed to Federal Drug Safety Task Force
- Complementary Therapies in Pediatrics: A Legal Perspective
- Alternative Meds Need to Be Tested
- Balance Food Marketing to Children With Nutrition Education Messages, American Dietetic Association Advises Institute of Medicine
- Mainstream and Alternative Medicine: Converging Paths Require Common Standards
- Studies: Alternative Meds Need to Be Tested
 |
 |
User Comments (0)
RSS Feeds